1.      Barut K, Adrovic A, Şahin S, et al. Juvenile idiopathic arthritis. Balkan Med J. 2017;34(2):90-101. doi: 10.4274/balkanmedj.2017.0111.

2.      Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(4):465-482. doi: 10.1002/acr.20460.

3.      Beukelman T, Xie F, Baddley JW, et al. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(5):1384-1389. doi: 10.1002/art.37866.

4.      Chistiakov DA, Savost'anov KV, Baranov AA. Genetic background of juvenile idiopathic arthritis. Autoimmunity. 2014;47(6):351-360. doi:10.3109/08916934.2014.889119

5.      Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-666. doi: 10.1002/art.24516.

6.      Davies K, Cleary G, Foster H, et al. BSPAR standards of care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(7):1406-1408. doi: 10.1093/rheumatology/kep460.

7.      De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395. doi: 10.1056/NEJMoa1112802.

8.      Demirkaya E, Ozen S, Bilginer Y, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol. 2011;29(1):111-116.

9.      Feldman BM, Birdi N, Boone JE, et al. Seasonal onset of juvenile rheumatoid arthritis. J Rheumatol. 1996;23(4):693-697. doi: 10.1016/s0022-3476(96)70115-4.

10.  Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti–IL-1 treatment distinguishes two subsets of patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-1515. doi: 10.1002/art.23437.

11.  Glerup M, Rypdal V, Arnstad ED, et al. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care Res (Hoboken). 2020;72(4):507-516. doi:10.1002/acr.23853

12.  Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268. doi: 10.1038/nrrheum.2015.179.

13.  Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22(5):561-566. doi: 10.1097/01.bor.0000381996.69261.71.

14.  Hinks A, Cobb J, Marion MC, et al. Dense genotyping of immune-related disease regions identifies multiple susceptibility loci for juvenile idiopathic arthritis. Nat Genet. 2013;45(6):664-669. doi: 10.1038/ng.2614.

15.  Immonen K, Savolainen A, Kautiainen H, et al. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J Rheumatol. 2008;35(5):907-912.

16.  Kessler EA, Becker ML. Therapeutic advancements in juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2014;28(2):293-313. doi: 10.1016/j.berh.2014.03.005.

17.  Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother. 2009;10(18):3049-3060. doi:10.1517/14656560903386300

18.  Martini A, Ravelli A, Avcin T, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46(2):190-197. doi:10.3899/jrheum.180168

19.  Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(9):2392-2401. doi:10.1002/art.10444.

20.  Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(2):545-555. doi: 10.1002/art.30128.

21.  Ombrello MJ, Arthur VL, Remmers EF, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906-913. doi:10.1136/annrheumdis-2016-210324

22.  Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. J Rheumatol. 2004;31(2):390-392.

23.  Ravelli A, Davì S, Bracciolini G, et al. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet. 2017;389(10072):909-916. doi:10.1016/S0140-6736(17)30065-X

24.  Ravelli A, Davi S, Minoia F, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(3):481-489. doi: 10.1136/annrheumdis-2015-208982.

25.  Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778. doi:10.1016/S0140-6736(07)60363-8

26.  Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 ACR/AF guideline for the treatment of juvenile idiopathic arthritis. Arthritis Rheumatol. 2019;71(6):846-863. doi: 10.1002/art.40884.

27.  Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396-2406. doi:10.1056/NEJMoa1205099

28.  Ruperto N, Brunner HI, Zuber Z, et al. Pharmacokinetic and safety profile of tofacitinib in children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2017;69(10):1966-1975. doi: 10.1186/s12969-017-0212-y.

29.  Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab in pediatric patients with juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(9):3096-3106. doi: 10.1002/art.22838.

30.  Savolainen A, Saila H, Kotaniemi K, et al. Magnitude of the genetic component in juvenile idiopathic arthritis. Ann Rheum Dis. 2000;59(12):1001. doi:10.1136/ard.59.12.1001

31.  Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.

32.  Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis in the biologic age. Rheum Dis Clin North Am. 2013;39(4):751-766. doi:10.1016/j.rdc.2013.05.004

33.  Tappeiner C, Klotsche J, Sengler C, et al. Risk factors and biomarkers for the development of uveitis in juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70(10):1685-1694. doi: 10.1002/art.40544. Epub 2018 Aug 21.

34.  Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in juvenile idiopathic arthritis. Arthritis Care Res. 2011;63(7):929-936. doi: 10.1002/acr.20497.

35.  Zaripova LN, Midgley A, Christmas SE, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135. doi: 10.1186/s12969-021-00629-8.